Comparisons of Analysis Methods for Proof-of-Concept Trials-Reference-Cited by-同舟云学术

Comparisons of Analysis Methods for Proof-of-Concept Trials

Published:2013-01 Issue:1 Volume:2 Page:23
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT: Pharmacometrics & Systems Pharmacology

Author:

Karlsson KE¹,Vong C¹,Bergstrand M¹,Jonsson EN¹²,Karlsson MO¹

Affiliation:

1. Department of Pharmaceutical Biosciences; Uppsala University; Uppsala Sweden

2. Exprimo NV; Mechelen Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/psp.2012.24/fullpdf

Reference50 articles.

1. FDA Challenge and Opportunity on the Critical Path to New Medical Products http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf 2004

2. The future of drug development: advancing clinical trial design;Orloff;Nat. Rev. Drug Discov.,2009

3. Price Waterhouse Coopers Pharma 2020 Series http://www.pwc.com/pharma 2007 2011

4. ASCPT Task Force for advancing pharmacometrics and integration into drug development;Goldberger;Clin. Pharmacol. Ther.,2010

5. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings;Barrett;J. Clin. Pharmacol.,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sparse item testing of clinical scales in neurology trials to alleviate burden to patients;Journal of Neurology;2024-08-30

2. Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points;CPT: Pharmacometrics & Systems Pharmacology;2024-08-23

3. Efficient Study Design and Analysis of Longitudinal Dose–Response Data Using Fractional Polynomials;Pharmaceutical Statistics;2024-07-28

4. The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA;The AAPS Journal;2024-02-27

5. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors;Clinical Pharmacology & Therapeutics;2024-01-16